U.S. Preparedness and Response to Increasing Clade I Mpox Cases in the Democratic Republic of the Congo - United States, 2024

MMWR Morb Mortal Wkly Rep. 2024 May 16;73(19):435-440. doi: 10.15585/mmwr.mm7319a3.

Abstract

Clade I monkeypox virus (MPXV), which can cause severe illness in more people than clade II MPXVs, is endemic in the Democratic Republic of the Congo (DRC), but the country has experienced an increase in suspected cases during 2023-2024. In light of the 2022 global outbreak of clade II mpox, the increase in suspected clade I cases in DRC raises concerns that the virus could spread to other countries and underscores the importance of coordinated, urgent global action to support DRC's efforts to contain the virus. To date, no cases of clade I mpox have been detected outside of countries in Central Africa where the virus is endemic. CDC and other partners are working to support DRC's response. In addition, CDC is enhancing U.S. preparedness by raising awareness, strengthening surveillance, expanding diagnostic testing capacity for clade I MPXV, ensuring appropriate specimen handling and waste management, emphasizing the importance of appropriate medical treatment, and communicating guidance on the recommended contact tracing, containment, behavior modification, and vaccination strategies.

MeSH terms

  • Centers for Disease Control and Prevention, U.S.
  • Democratic Republic of the Congo / epidemiology
  • Disease Outbreaks* / prevention & control
  • Humans
  • Monkeypox virus / isolation & purification
  • Mpox (monkeypox)* / epidemiology
  • United States / epidemiology